AKT1 and breast cancer: Consequently, Rac plays a significant role in resistance to EGFR/HER+ breast cancer by acting downstream of EGFR/HER2 therapy resistance mechanisms such as Ras/MAPK and PI3-K/Akt signaling [33–43].